https://orcid.org/0000-0001-9550-0056
References
- Allolio B, Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006;91(6):2027–2037. doi:10.1210/jc.2005-263916551738
- Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 international union against cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer. 2009;1(15):243–250. doi:10.1002/cncr.24030
- Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol. 1984;8(3):163–169. doi:10.1097/00000478-198403000-000016703192
- Ribeiro R, Figueiredo B. Childhood adrenocortical tumours. Eur J Cancer. 2004;40(8):1117–1126. doi:10.1016/j.ejca.2004.01.03115110875
- Gundgurthi A, Kharb S, Dutta MK, et al. Childhood adrenocortical carcinoma: case report and review. Indian J Endocrinol Metab. 2012;16(3):431–435.22629514
- Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol. 2003;169:5211. doi:10.1016/S0022-5347(05)64023-2
- Han W, Li J, Qin H, et al. Diagnosis and treatment of adrenal cortical carcinoma in children. Chin J Pediatr Surg. 2015;36(1):44–48.
- Ye JN, Wang WQ. Progress in pharmaceutical treatment for adrenocortical carcinoma. Chin J Endocrinol Metab. 2011;027(1):91–94.
- Lughezzani G, Sun M, Perrotte P, et al. The European network for the study of adrenal tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer. 2010;46(4):713–719.20044246
- Conzo G, Gambardella C, Candela G, et al. Single center experience with laparoscopic adrenalectomy on a large clinical series. BMC Surg. 2018;18(1):2. doi:10.1186/s12893-017-0333-829325527
- Conzo G, Pasquali D, Gambardella C, et al. Long-term outcomes of laparoscopic adrenalectomy for cushing disease. Int J Surg. 2014;12(Suppl 1):S107–S111. doi:10.1016/j.ijsu.2014.05.03624862670
- Liu T, Jia H, Kong CZ. Diagnosis and treatment of primary nonfunctioning adrenal cortical carcinoma. J Mod Oncol. 2011;03:95–97.
- Niu S, Zhang YS. Advance in diagnosis and treatment of adrenocortical tumor. Chin J Endocr Surg. 2016;10(3):248–251.
- Xu LY, Xu YZ, Lian JP, et al. The diagnostic and prognostic value of EGFR, IGF1R, Ki67 and weiss score for adrenocortical tumors. J Mod Urol. 2016;21:417.
- Nakamura Y, Yamazaki Y, Felizola SJ, et al. Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis. Endocrinol Metab Clin North Am. 2015;44(2):399–410. doi:10.1016/j.ecl.2015.02.00726038208
- Fassnacht M, Allolio B. What is the best approach to an apparently nonmetastatic adrenocortical carcinoma? Clin Endocrinol. 2010;73:561. doi:10.1111/j.1365-2265.2010.03867.x
- Skogseid B, Bandin E, Fassnacht M et al. Experience from an ongoing Phase III study: FIRM-ACT. Abstract Book of the 2nd Annual International Adrenal Cancer Symposium: Clinicaland Basic Science; 2008:465.
- Berruti A, Terzolo M, Sperone P, et al. Etoposide doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer. 2005;12:657–666. doi:10.1677/erc.1.0102516172198
- Samnotra V, Vassilopoulou—Sellin R, Fojo AT, et al. A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma(ACC). J Clin Oncol. 2007;25(Suppl 18):15527.
- Quinkler M, Hahner S, Wortmann S, et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab. 2008;93(6):2057–2062. doi:10.1210/jc.2007-256418334586
- O’Sullivan C, Edgerly M, Velarde M, et al. The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. J Clin Endocrinol Metab. 2014;99(4):1291–1297. doi:10.1210/jc.2013-229824423320